What Clinicians and Researchers Are Saying About Our Data
Author: Rany Aburashed, DO
Published On: November 30, 2025
Alzheimer’s disease research has reached a turning point. What was once limited to invasive spinal taps and costly imaging can now be achieved through a simple blood draw, thanks to the precision of blood-based biomarkers.
Among them, p-tau217 data have emerged as the most accurate and practical indicator of Alzheimer’s to date.
At Neurogen Biomarking, our mission is to make these breakthroughs clinically accessible. By combining cutting-edge p-tau217 biomarker testing with expert clinician interpretation and digital cognitive tools, we’re helping people take control of their memory health before a significant decline.
The Science Behind Neurogen’s P-tau217 Data
The foundation of Neurogen’s biomarker testing is built on the research of Dr. Elisabeth Thijssen, our Chief Scientific Officer.
Dr. Thijssen is a globally recognized neuroscientist whose work at Amsterdam UMC, UCSF, and Indiana University helped establish p-tau217 as one of the most reliable biomarkers for Alzheimer’s disease.
Her independent academic studies have demonstrated that plasma p-tau217 levels can mirror cerebrospinal fluid (CSF) and PET scan results with remarkable accuracy.
Building on years of global research, recent studies corroborate Dr. Thijssen's and her peers' findings, confirming that plasma p-tau217 testing performs reliably across multiple platforms and clinical environments.
These findings, validated across international cohorts, now guide clinicians in identifying Alzheimer’s disease years before symptoms appear.
How Neurogen Translates Research into Real-World Care
Neurogen takes proven research and transforms it into an ecosystem that allows memory health testing from the comfort of your home.
Our model pairs blood-based biomarker testing with digital cognitive assessments and expert clinical interpretation, bridging the gap between the lab and the patient.
The ecosystem continues to evolve through meaningful industry and research collaborations that strengthen both accuracy and accessibility.
Partnerships with diagnostic innovators and digital health leaders have advanced our testing processes and cognitive insights. And our ongoing participation in major conferences shows our dedication to the mission of proactive Alzheimer’s diagnosis and treatment.
Recent Collaborations and Expansions:
- Quanterix Agreement: This partnership enables us to use advanced testing technology to improve the precision and reliability of its blood-based biomarker results.
- Linus Health Integration: By combining biomarker testing with digital cognitive assessments, this collaboration helps provide a more complete picture of brain health for early detection.
- AAIC 2025 Presentation: We presented real-world p-tau217 findings to the international Alzheimer’s research community, highlighting how the data perform in the real world and support clinical decision-making.
What Leading Researchers Are Saying
As more people learn about the promise of blood-based biomarkers, Neurogen continues to be part of a growing conversation about progress in memory health.
Clinicians, researchers, and advocates are recognizing our role in bringing complex science into everyday care, making advanced testing more straightforward, more reliable, and available to more people who need it most.
Clinical Validation and Early Treatment Impact
Early detection has become the defining factor in effective Alzheimer’s treatment. Since disease-modifying therapies are most effective in early stages, accurate diagnosis now determines who benefits most.
Dr. Michelle Mielke (Wake Forest University)
Dr. Mielke, a leading authority in gerontology and geriatric medicine, highlights how precision testing transforms treatment outcomes:
“Understanding the cause of cognitive impairment at the earliest possible time is critical for identifying the most appropriate treatment pathways. The combination of Neurogen’s blood-based biomarker and ecosystem for explanation of results and care can make a big difference in patients’ treatment plans.”
Dr. Cara Leahy (Memorial Healthcare)
“The latest FDA-approved Alzheimer's disease treatments slow the progression of the disease, but they are only available to patients in the earliest stages. Therefore, an early diagnosis of Alzheimer's disease is now as important as an early diagnosis of cancer.”
Diagnostic Precision and Clinical Accessibility
Beyond timing, increased accuracy and accessibility will change how we approach Alzheimer’s diagnostics.
Researchers agree that blood-based biomarkers must not only perform reliably but also be usable across healthcare settings.
Dr. Thomas Karikari (University of Pittsburgh
As Director of the Biofluid Biomarker Laboratory, Dr. Karikari sees Neurogen’s neurologist-integrated testing model as a key to scaling early detection:
“Neurogen provides a one-stop destination for high-performance blood tests and expert clinicians to help you interpret the results and develop a plan forward.”
Dr. Nicholas Ashton (Banner Health)
Dr. Ashton, Senior Director of the Biomarker Program, confirms the readiness of blood-based Alzheimer’s testing for widespread adoption:
“Blood tests for an accurate pathological diagnosis of Alzheimer's disease are now a reality. These tests will revolutionize the clinical management of cognitive decline, and Neurogen is committed to ensuring that these tests are not only accessible and user-friendly, but most importantly, precise and reliable.”
Global Research Consensus
Worldwide, researchers are aligned to make accurate early detection accessible. Blood-based biomarkers like p-tau217 are enabling earlier diagnoses and better ways to own your memory health.
Dr. Jeffrey Dage (Indiana University)
A senior research professor of neurology, Dr. Dage, affirms how combining biomarker and cognitive testing is transforming how we diagnose Alzheimer’s:
“Neurogen's approach to early Alzheimer's disease detection through blood-based biomarkers and digital cognitive testing is transformative. Their method enables easier access to experts trained in these diagnostic aids, facilitating accurate and timely diagnoses.”
Dr. Inge Verberk (Amsterdam UMC)
Dr. Verberk, an expert in biomarker pre-analytics, connects Neurogen’s mission with the global movement toward accessible diagnostics:
“The development of an accurate blood test for Alzheimer’s disease has revolutionized early disease detection. Neurogen is dedicated to making this test accessible to those in need.”
The Broader Validation of Neurogen’s Approach
From independent academic labs to integrated clinical platforms, the science surrounding p-tau217 research tells a promising story of accuracy, accessibility, and impact.
Under Dr. Thijssen’s leadership, we ensure that every test reflects validated biomarker standards and contributes to a broader ecosystem focused on prevention-first memory health.
And our ongoing partnerships, conference presentations, and collaborations reinforce our commitment to scientific transparency and clinical excellence.
What This Means for Participants and Clinicians:
- Earlier, more confident Alzheimer’s diagnoses.
- Trusted data that patients and providers can rely on.
- Clearer pathways to treatment and clinical trials.
From Discovery to Action: Join the Neurogen Ecosystem Today
Blood-based biomarkers like p-tau217 are changing how we approach Alzheimer’s care, and Neurogen is here to make them more accessible. By uniting peer-reviewed science with neurologist expertise, we offer at-home testing that’s not just accurate but truly actionable.
Know Before it Shows
Explore how Neurogen’s testing ecosystem works and join the movement toward proactive memory health.
